MedDataX Logo

SHARE: Simple HAART With Abacavir, Reyataz, and Epivir

NCT ID: NCT00426296

Last Updated: 2007-11-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Study Classification

INTERVENTIONAL

Study Start Date

2006-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

SHARE: Simple HAART with Abacavir, Reyataz, and Epivir

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Open-label, multicenter study of ABC/3TC + ATV in subjects who have completed at least 24 weeks of treatment on ABC/3TC+ATV/RTV as their first line regimen and have plasma HIV-1 RNA \<50 copies/mL at entry

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections Lipodystrophy

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

HIV Reyataz atazanavir Norvir ritonavir Boosted Lipodystrophy Treatment Experienced

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

atazanavir (Reyataz)

Intervention Type DRUG

ritonavir (Norvir)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Currently taking abacavir/lamivudine (Epzicom) in combination with atazanavir (Reyataz) boosted with ritonavir (Norvir) as first antiretroviral regimen
* Viral load \<50 copies/ml

Exclusion Criteria

* Viral load \>50 copies/ml
* Having taken more than one antiretroviral regimen
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

GlaxoSmithKline

INDUSTRY

Sponsor Role collaborator

Clinical Alliance for Research & Education - Infectious Diseases, LLC.

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Richard A Elion, MD

Role: PRINCIPAL_INVESTIGATOR

Whitman-Walker Clinic

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Whitman-Walker Clinic

Washington D.C., District of Columbia, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Richard A. Elion, MD

Role: CONTACT

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Richard Elion, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

COL102060

Identifier Type: -

Identifier Source: org_study_id